Evogene Ltd. (TASE: EVGN)
Health Care · Biotechnology · IL
₪1.73
-9.27% today · -60.1% 1Y
Evogene Ltd. (TASE: EVGN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.04M and employs 52 people.
Over the last twelve months the share price has lost 60.1%, trading between 1.15 and 4.79.
Tweenvest scores Evogene Ltd. across four factors: quality 27/100, value 47/100, growth 62/100. Its strongest factor is growth.
EVGN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.04M
- Revenue (TTM)
- $1.84M
- P/E
- —
- EPS
- -1.37
- Dividend yield
- —
- Beta (5Y)
- 0.68
- 52-week high
- ₪4.79
- 52-week low
- ₪1.15
- Avg volume (3M)
- —
- Shares outstanding
- 10.41M
- Employees
- 52
- Next earnings
- —
About Evogene Ltd.
Evogene Ltd. is a computational biology firm specializing in the identification and advancement of products across human health and agricultural sectors. Its proprietary Computational Predictive Biology (CPB) platform leverages deep biological insights, big data, and artificial intelligence to precisely uncover and guide the creation of life science solutions, including novel microbes, small molecules, and genetic components. The company operates through distinct divisions: Agriculture, Human Health, and Industrial Applications. The Agriculture division concentrates on improving crop performance through the development of advanced seed traits, agricultural chemicals, and biological products for crops like corn, soybean, wheat, rice, and cotton. The Human Health division focuses on pioneering microbiome-based treatments for conditions such as immuno-oncology, gastrointestinal ailments, and antibiotic-resistant infections, and also offers medical cannabis products. The Industrial Applications segment is dedicated to developing improved castor bean varieties for various industrial feedstock requirements. Evogene has a global footprint, conducting business in the United States, Israel, Brazil, and other international markets. It maintains significant partnerships, including agricultural collaborations with BASF SE, Corteva, and Bayer, and a medical cannabis development agreement with Cannbit Ltd. through its subsidiary, Canonic Ltd. Established in 1999, Evogene Ltd. is headquartered in Rehovot, Israel.
- ISIN
- IL0011050551
- Founded
- 1999
- Listed since
- Jun 13, 2007
- Exchange
- The Tel-Aviv Stock Exchange
- Currency
- ILS
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.18 | -0.13% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.98 | +0.26% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.96 | +0.15% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $549.00 | +0.26% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $834.94 | +0.78% |
| argenx SEENXTBR: ARGX | $63.06B | €872.80 | +1.00% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.09 | +1.58% |
Figures last refreshed Aug 18, 2026.